Innovent Biologics (IVBXF) Receives a Buy from Huatai Securities

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released yesterday, from Huatai Securities maintained a Buy rating on Innovent Biologics, with a price target of HK$129.54. The company’s shares closed yesterday at HK$85.80.

Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$135.90, implying a 58.39% upside from current levels. In a report released on November 2, Bernstein also maintained a Buy rating on the stock with a HK$128.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.